Corporate News

US patent granted

April 2018

The US Patent Office has granted to INMUNOTEK the patent US9901633B2. This refers to new glycoconjugates performed with non-oxidized mannan derived from S. cerevisiae that can be used for designing novel vaccines targeting dendritic cells. This approach is being used for the development of allergy vaccines with improved immunomodulatory properties.
More info

Inmunotek has made the 2018 Inc.5000 list

March 2018

Inc. magazine revealed the 2018 Inc. 5000 list of fastest-growing private companies in Europe.  With an accumulated growth of more than 80%, INMUNOTEK has made into this ranking.
More info

Japan patent granted

February 2018

The Japan Patent Office has granted to INMUNOTEK the patent JP6285012B2 . This refers to new glycoconjugates performed with non-oxidized mannan derived from S. cerevisiae that can be used for designing novel vaccines targeting dendritic cells. This approach is being used for the development of allergy vaccines with improved immunomodulatory properties.
More info

INMUNOTEK celebrates its 25th anniversary

December 2017

INMUNOTEK has celebrated its 25th anniversary on December 1st with a party at the Círculo de Bellas Artes in Madrid. Its more than 200 employees have been able to enjoy an emotional event where there has been music and humor from Javier Horche and his group.
More info

Innovative SME

November 2017

Inmunotek has been awarded as an Innovative SME (State Confederation of Small and Medium-sized Enterprises) at the Technology and Innovation Awards.
More info